The markups helped the PBMs reap $7.3 billion from 2017 to 2022, the FTC found. The PBMs—owned by insurers Cigna, CVS Health and UnitedHealth Group—are supposed to help keep drug costs low for ...
The practice inflated costs for consumers and insurers on key treatments for cancer, multiple sclerosis, HIV, organ transplants, and other conditions and procedures, the FTC said. The report ...